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Background: A large number of single nucleotide polymorphisms (SNPs) associated with cervical cancer have been
identified through candidate gene association studies and genome-wide association studies (GWAs). However,
some studies have yielded different results for the same SNP. To obtain a more comprehensive understanding, we
performed a meta-analysis on previously published case–control studies involving the SNPs associated with cervical
cancer.
Methods: Electronic searches of PubMed and Embase were conducted for all publications about the association
between gene polymorphisms and cervical cancer. One-hundred and sixty-seven association studies were included
in our research. For each SNP, three models (the allele, dominant and recessive effect models) were adopted in the
meta-analysis. For each model, the effect summary odds ratio (OR) and 95% CI were calculated. Heterogeneity between
studies was evaluated by Cochran’s Q test. If the p value of Q test was less than 0.01, a random effect model was used;
otherwise, a fixed effect model was used.
Results: The results of our meta-analysis showed that: (1) There were 8, 2 and 8 SNPs that were significantly associated
with cervical cancer (P < 0.01) in the allele, dominant and recessive effect models, respectively. (2) rs1048943 (CYP1A1
A4889G) showed the strongest association with cervical cancer in the allele effect model (1.83[1.57, 2.13]); in addition,
rs1048943 (CYP1A1 A4889G) had a very strong association in the dominant and recessive effect model. (3) 15, 11 and
10 SNPs had high heterogeneity (P < 0.01) in the three models, respectively. (4) There was no published bias for most
of the SNPs according to Egger’s test (P < 0.01) and Funnel plot analysis. For some SNPs, their association with cervical
cancer was only tested in a few studies and, therefore, might have been subjected to published bias. More studies on
these loci are required.
Conclusion: Our meta-analysis provides a comprehensive evaluation of cervical cancer association studies.
Keywords: Cervical cancer, Single nucleotide polymorphism, Susceptibility, Meta-analysisBackground
Cervical cancer is a serious disease which affects
women’s health. It is the third most common malignancy
in women worldwide [1,2]. However, in China, it is the
second disease only to breast cancer in the morbidity of
malignancy in women. More than 200,000 women die
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unless otherwise stated.one of the highest rates from cervical cancer in the
world, and it is six times higher than other developed
countries. However, trend of incidence age of pa-tients
with cervical cancer gradually gets younger [3,4] Cervical
cancer is a complex disease that results from the inter-
action between gene mutations and the environment.
Epidemiological and laboratory-based studies have iden-
tified that human papilloma virus (HPV) infection con-
tributes to cervical cancer. More than 90% cases of
cervical cancer are caused by HPV infection, and type
16 and 18 are the most common types [5,6]. Although
most sexually active women have been infected withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to clear the virus. So only a very small proportion of
women with persistent HPV infection ultimately develop
into cervical cancer and it indicated that HPV infection
is a necessary but not sufficient risk factor for the origin
and development of cervical cancer. Consequently, host
genetic differences in the effective host immune re-
sponse may influence the risk for cervical cancer among
those infected with HPV. Therefore, it is very important
to identify the gene loci related to cervical cancer origin
and progression. Over the past few decades, the genetic
susceptibility of cervical cancer has been examined by
candidate gene association and genome-wide association
studies, and researchers have found that the most im-
portant SNP was located in 6q12, within the human
leukocyte antigen (HLA), or MHC, genes [7,8]. The
HLA-II (DRB1) gene contains many mutations, and
these mutations result in changes of the amino acid se-
quence of HLA-II. Many studies have reported that
HLA-II (DRB1) is strongly associated with cervical can-
cer. However, the structure of the DRB1 gene is com-
plex, and thus, it is very difficult to analyze SNPs of
DRB1 with the standard SNP gene effect model. At the
same time, other genetic intervals and SNPs have been
reported to be related to the pathogenesis of cervical
cancer and to play an important role in this process.
Therefore, our meta-analysis does not include SNPs in
the HLA genes, but focuses on these other reported
SNPs. Although researchers have had great success in
their research on the gene mutations associated with cer-
vical cancer, many problems still remains. Some studies
show conflicting results for the same SNP. For example, in
studies of the relationship between TNF-α-308G > A with
the pathogenesis of cervical cancer, Duarte I [9] found that
this SNP is significantly associated with cervical cancer
(OR = 1.8, 95% CI [1.21, 2.69]). However, Gostout BS
found that TNF-α-308G >A does not increase the inci-
dence rate of cervical cancer (OR (95% CI) =0.98 [0.64,
1.50]) [10]. These controversial results may be caused by
small sample sizes, racial or ethnic differences, or clinical
and genetic heterogeneity. Therefore, it is very important
to assess whether the combined evidence shows an
association between a SNP and cervical cancer. Meta-
analysis is a very effective method by which the results of
many studies with small sample sizes are combined.
Through this method, the relationship of some SNPs, such
as TNF-α-308G > A and TNF-α-238G > A, associated with
cervical cancer has been proven. TNF-α-308G > A can
increase the susceptibility of cervical cancer, while
TNF-α-238G >A can significantly decrease its susceptibil-
ity [11]. However, only one or two SNPs were identified in
a previously published meta-analysis on SNP loci and cer-
vical cancer. To comprehensively and systematically assess
the association between all of the available SNPs andcervical cancer susceptibility, we searched the PubMed
database and Embase and performed a meta-analysis on
the results of the selected studies. For each SNP, three
genetic models were considered: the allele, dominant and
recessive effect models. We also examined the heterogen-
eity between studies and the existence of published bias
using Egger’s test. As far as we know, this is the most de-
tailed meta-analysis of SNPs and cervical cancer to date.
Methods
Data collection
The PubMed and Embase were searched for the appropri-
ate studies using the following keywords: (polymorphism
OR mutation OR single nucleotide polymorphisms OR
genome-wide association study OR SNP OR GWAS)
AND (cervical cancer OR cervical carcinoma). The studies
to be included in the meta-analysis were selected in ac-
cordance with the following criteria: (1) the articles must
have been published between January of 1990 and June of
2014; (2) the studies must employ a case–control design
and must examine the association between SNPs and cer-
vical cancer; (3) data on the SNP genotypes of patients
and controls must be available; (4) the studies must be
published as a full paper, not as a meeting abstract or re-
view; and (5) NOT-HLA. For each study, we extracted the
following information: the gene polymorphisms, first au-
thor, date of publication, title, population and number of
cases and controls. Then, we choose those SNPs which
published at least 2 times. Using these criteria, 152 papers
involving 42 SNPs were selected for the meta-analysis
(Figure 1).
Selection of the genetic model
To comprehensively analyze the association between
SNPs and cervical cancer, we adopted three genetic
models: the allele effect model, the dominant effect
model, and the recessive effect model. In these models,
we assumed that each SNP marker locus has two alleles
(A and a). A is the high-risk candidate allele, and a is
the low-risk allele. The three models are described as
follows:
1) Allele model: the effect of the A allele vs. the effect
of the a allele;
2) Dominant model: If the SNP produces a cervical
cancer phenotype when present in either one or two
copies of the A allele, i.e., the AA + Aa vs. aa
genotypes.
3) Recessive model: If only the aa genotype exists, the
SNP produces a cervical cancer phenotype.
All meta-analysis were performed using RevMan 5.2
software. For each model, we calculated the OR value
and 95% CI for the individual study. To evaluate the
Figure 1 Flow chart shows study selection procedure.
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we performed a sensitivity analysis by sequentially re-
moving each article at a time.
Evaluation of heterogeneity
Cochran’s Q test was used to evaluate the heterogeneity of
between- and within-study variation. In fact, Cochran’s Q
test is simply a chi-square test [12]. The null hypothesis
was that all studies were evaluating the same effect.
Rejecting the null hypothesis meant that heterogeneity
exists between studies. P < 0.01 was considered to be
significant. Another indicator of heterogeneity is I [2],
which measures the degree of inconsistency across stud-
ies. The formula is as follows: I2 = (Q-(k-1))/Q*100%
(where k is the number of studies). When the value of I2
is more than 25%, 50% or 75%, low-, mid- or high-grade
heterogeneity is present, respectively [13-16].
Evaluation of the statistical association between the
identified SNPs and cervical cancer
In this meta-analysis, Cochran’s Q test was used to evalu-
ate the heterogeneity between studies. If the Q-statisticwas not significant, we considered that all of the differ-
ences between studies were caused by sampling error.
Then, we selected the fixed effects model in the meta-
analysis. In contrast, if the p value was significant (P < 0.01),
meaning that heterogeneity exists between studies, we
chose the random effects model.
Evaluation of publication bias
Funnel plots were used to intuitively assess publication
bias. The horizontal ordinate of the Funnel plots corre-
sponded to the study effects. If the variable was continu-
ous, the effects are just shown as the original value;
otherwise, the effects are shown as a log value. The ver-
tical ordinate corresponds to the sample size, standard
error or accuracy. The smaller the sample, the more
scattered the distribution; and the larger the sample size,
the more concentrated the distribution. If there is no
bias, the Funnel plot is symmetrical. In contrast, if the
diagram is asymmetrical, it means that publication bias
exists. In addition, Egger’s test was used to quantitatively
assess the symmetry of the Funnel plots [17,18]. Egger’s
test cannot be used in a meta-analysis when the number
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test for SNPs with larger than or equal to 2 studies.
Egger’s test was carried out using Stata 12.0 software.
Results
In our search for eligible studies and loci, we input the
aforementioned keywords into the PubMed and Embase
and then obtained 2552 studies. Screened by the criteria
mentioned in the data collection, 152 of these 2552 studiesTable 1 Meta-analysis results under the allele model
SNP Comparison Gene symbol No. Q
rs1048943 G/A CYP1A1 A4889G 8 12.72
rs3212227 A/C IL-12B 2 3.97
rs2279744 T/G MDM2 2 16.6
rs16944 C/T IL-1β 4 10.06
rs187084 T/C TLR9 T1486C 3 2.18
rs4646903 C/T CYPA1 T6235C 8 33.46
rs568408 G/A IL-12A 2 0.05
rs1800872 C/A IL-10 C592A 5 4.69
rs1800795 G/C IL-6 2 0
rs11134527 A/G pri-miR-218 2 0.72
rs1800629 G/A TNF-α-308 15 56.89
rs1801275 A/G IL-4R 2 0.24
rs1052134 Ser326Cys OGG1 2 0
rs603965 G/A CCND1 6 6.6
rs361525 G/A TNF-α-238 8 805.51
rs5742909 T/C CTLA-318 5 18.55
rs62559044 A/T IFN-r A874T 4 26.88
rs1801133 T/C MTHFR C677T 8 35.6
rs352140 G/A TLR9 G2848A 3 0.26
rs833061 T/C VEGF T460C 2 0.39
rs11549465 C/T HIF1A C1772T 2 11.76
rs1805087 A/G MTR A2756G 2 32.02
rs763110 T/C FASL T844C 2 13.02
rs1800896 G/A IL-10 G1082A 8 5.77
rs3021097 C/T IL-10 C819T 2 3.09
rs1800682 G/A Fas 9 22.37
rs1801131 A/C MTHFR A1298C 2 2.84
rs3116496 C/T CD28 3 13.94
rs1799864 A/G CCR2 3 84.35
rs5275 C/T COX-2 2 1.1
rs861539 C/T XRCC3Codon241 5 16
rs3025039 C/T VEGF C936T 2 1.19
rs2031920 c1/c2 CYP2E1 2 0.2
rsl801270 C/A p21 codon 31 7 55.68
rs4404252 T/C ICOS 2 0.08
No, number of studies; OR, combined odds ratio; CI, confidence interval; P, P value.involving 42 SNPs were included in our meta-analysis
(Additional file 1: Table S1 and Additional file 2). The
Cohen’s Kappa value was 0.79(P < 0.05). Each of the 42
SNPs was reported in at least two studies. The number of
studies for each locus was also counted. Fourteen SNPs
were reported more than five times, and five SNPs were
reported more than 10 times. The five SNPs genotypes in
the cases and controls were extracted for subsequent
analysis.Q-P I2 Model 95% CI P
0.08 0.45 Fixed 1.75[1.49,2.05] <0.00001
0.05 0.75 Fixed 0.75[0.64,0.87] 0.0001
<0.00001 0.94 Random 0.64[0.50,0.82] 0.0004
0.02 0.7 Fixed 0.79[0.69,0.90] 0.0006
0.34 0.08 Fixed 0.84[0.75,0.95] 0.005
<0.00001 0.79 Random 1.59[1.39,1.81] 0.005
0.83 0 Fixed 0.78[0.66,0.93] 0.006
0.32 0.15 Fixed 0.85[0.76.0.96] 0.007
0.94 0 Fixed 0.69[0.51,0.92] 0.01
0.39 0 Fixed 1.11[1.02,1.21] 0.02
<0.00001 0.77 Random 0.82[0.68,0.98] 0.03
0.63 0 Fixed 1.18[0.98,1.42] 0.09
0.96 0 Fixed 1.26[0.94,1.68] 0.12
0.25 0.24 Fixed 0.92[0.82,1.03] 0.14
<0.00001 0.99 Random 2.90[0.65,12.9] 0.16
0.001 0.78 Random 1.39[0.87,2.21] 0.17
<0.00001 0.89 Random 1.10[0.94,1.29] 0.21
<0.00001 0.8 Random 0.87[0.67,1.12] 0.27
0.61 0 Fixed 1.09[0.92,1.29] 0.30
0.53 0 Fixed 1.14[0.86,1.50] 0.35
0.0006 0.91 Random 0.56[0.13,2.32] 0.42
<0.00001 0.97 Random 1.95[0.34,11.18] 0.45
0.0003 0.92 Random 0.81[0.47,1.40] 0.45
0.441 0 Fixed 1.00[0.91,1.09] 0.45
0.08 0.68 Fixed 0.92[0.72,1.16] 0.47
0.004 0.64 Random 1.06[0.90,1.24] 0.48
0.09 0.65 Fixed 1.08[0.86,1.36] 0.50
0.0009 0.86 Random 1.14[0.76,1.71] 0.52
<0.00001 0.98 Random 1.30[0.46,3.69] 0.62
0.29 0.09 Fixed 0.95[0.75,1.22] 0.70
0.003 0.75 Random 0.92[0.58,1.44] 0.70
0.28 0.16 Fixed 1.06[0.77,1.45] 0.72
0.66 0 Fixed 1.03[0.71,1.50] 0.87
<0.00001 0.89 Random 0.97[0.69,1.38] 0.87
0.77 0 Fixed 1.01[0.86,1.18] 0.93
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For each SNP, the OR and 95% CI of the A allele (A vs. a)
were calculated for each study, and the heterogeneity be-
tween studies was tested. In our analysis of heterogeneity,
we identified 15 SNPs with a Q test P value of <0.01.
Thus, for the meta-analysis of these SNPs, we used the
random effects model. For the remaining SNPs that did
not show heterogeneity, we used the fixed effects model.
The meta-analysis showed that 8 SNPs were significantly
associated with cervical cancer (P < 0.01, Table 1). Among
these 8 SNPs, only 2 SNPs had heterogeneity (p < 0.00001
and p < 0.00001 for rs2279744 and rs4646903, respectively).Table 2 Meta-analysis results under the dominant genetic mo
SNP Comparison Gene symbol No. Q
rs1048943 GG + GA/AA CYP1A1 A4889G 8 8.8
rs11134527 AA + AG/GG pri-miR-218 2 0
rs2279744 TT + TG/GG MDM2 2 3.32
rs4646903 CC + CT/TT CYPA1 T6235C 8 33.12
rs1801275 AA + AG/GG IL-4R 2 0.15
rs1800872 CC + AC/AA IL-10 C592A 5 1.88
rs62559044 AA + AT/TT IFN-r A874T 4 2.47
rs1800896 GG + GA/AA IL-10 G1082A 8 9.96
rs1800795 GG + GC/CC IL-6 3 4.46
rs1052134 Ser326Cys OGG1 2 1.42
rs352140 GG + GA/AA TLR9 G2848A 3 4.81
rs3212227 AA + AC/CC IL-12B 2 2.03
rs833061 TT + TC/CC VEGF T460C 2 1.33
rs1805087 AA + AG/GG MTR A2756G 2 2.72
rs1801133 TT + TC/CC MTHFRC677T 8 28.67
rs5742909 TT + TC/CC CTLA-318 5 19.13
rs1800629 GG + GA/AA TNF-α-308 15 52.19
rs187084 TT + TC/CC TLR9T1486C 3 2.4
rs16944 CC + CT/TT IL-1β 4 16.3
rs568408 GG + GA/AA IL-12A 2 0.64
rs1800682 GG + GA/AA Fas 9 63.31
rs763110 TT + TC/CC FASL T844C 2 13.18
rsl801270 CC + CA/AA p21 codon 31 7 31.99
rs1799864 AA + GA/GG CCR2 3 128
rs361525 GG + GA/AA TNF-α-238 8 399
rs3116496 CC + CT/TT CD28 3 17.6
rs3021097 CC + CT/TT IL-10 C819T 2 1.27
rs603965 GG + GA/AA CCND1 6 4.24
rs1801131 AA + CA/CC MTHFR A1298C 2 2.95
rs3025039 CC + CT/TT VEGF C936T 2 2.28
rs5275 CC + CT/TT COX-2 2 0.03
rs4404252 TT + TC/CC ICOS T/C 2 0.02
No, number of studies; OR, combined odds ratio; CI, confidence interval; P, P value.The OR values of rs2279744 and rs4646903 were 0.64
(95% CI [0.50, 0.82]) and 1.59 (95% CI [1.39, 1.81]) in the
random effects model. For the remaining 6 SNPs, the fixed
effects model was used. The most significant locus was
rs1048943 (CYP1A1 risk allele G/A) (p < 0.00001). The
pooled summary OR based on the fixed effects model was
1.75 (95% CI [1.49, 2.05]) (Forest plot along with funnel
plot was shown in Additional file 3), suggesting that the
rs1048943 G allele confers susceptibility to cervical cancer.
In addition, the publication bias was tested using Funnel
plots and Egger’s test, and no publication bias was
observed.del
Q-P I2 Model 95% CI P
0.12 0.43 Fixed 0.40[0.25,0.66] 0.0002
0.98 0 Fixed 1.25[1.06,1.47] 0.007
0.07 0.7 Fixed 0.55[0.34,0.88] 0.01
<0.0001 0.79 Random 1.65[1.12,2.43] 0.01
0.69 0 Fixed 1.70[1.07,2.68] 0.02
0.76 0 Fixed 0.79[0.63,0.98] 0.03
0.48 0 Fixed 1.58[1.15,2.15] 0.04
0.13 0.4 Fixed 1.19[0.99,1.44] 0.06
0.11 0.55 Fixed 0.52[0.26,1.07] 0.08
0.23 0.29 Fixed 1.59[0.93,2.72] 0.09
0.09 0.58 Fixed 1.25[0.95,1.63] 0.10
0.15 0.51 Fixed 0.77[0.56,1.06] 0.11
0.25 0.25 Fixed 1.75[0.85,3.59] 0.13
0.1 0.63 Fixed 1.64[0.83,3.27] 0.16
0.0002 0.76 Random 0.81[0.60,1.10] 0.17
0.0007 0.79 Random 1.43[0.86,2.39] 0.17
<0.00001 0.75 Random 0.82[0.57,1.18] 0.28
0.3 0.17 Fixed 0.88[0.71,1.11] 0.29
0.001 0.82 Random 0.76[0.45,1.28] 0.30
0.42 0 Fixed 0.79[0.46,1.35] 0.39
<0.00001 0.87 Random 1.20[0.77,1.87] 0.41
0.0003 0.92 Random 0.77[0.38,1.52] 0.45
<0.0001 0.81 Random 0.83[0.51,1.35] 0.46
<0.0001 0.98 Random 1.65[0.35,7.82] 0.52
<0.0001 0.98 Random 1.98[0.24,16.2] 0.53
0.0002 0.89 Random 1.14[0.69,1.88] 0.61
0.26 0.21 Fixed 1.05[0.73,1.49] 0.80
0.52 0 Fixed 0.98[0.82,1.17] 0.80
0.09 0.66 Fixed 1.07[0.63,1.81] 0.81
0.13 0.56 Fixed 1.08[0.57,2.04] 0.82
0.86 0 Fixed 0.98[0.73,1.32] 0.91
0.88 0 Fixed 0.99[0.64,1.54] 0.98
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Based on the dominant model (AA + Aa vs. aa geno-
type), we tested the heterogeneity between studies. Het-
erogeneity was found for eleven SNPs (P < 0.01). For
these SNPs, the random effects model was used in the
meta-analysis. For the others that did not show hetero-
geneity, the fixed effects model was used. Table 2 lists all
of the SNPs with dominant genetic model, and we found
a significant association between two of these SNPs and
cervical cancer. These two SNPs had no heterogeneity,
and the fixed effects model was adopted. rs1048943Table 3 Meta-analysis results under the recessive genetic mo
SNP Comparison Gene symbol No. Q
rs1048943 GG/GA + AA CYP1A1A4889G 8 14.4
rs16944 CC/CT + TT IL-1β 4 3.37
rs4646903 TT/TC + CC CYPA1T6235C 8 12.74
rs3212227 AA/AC + CC IL-12B 2 1.36
rs187084 TT/TC + CC TLR9 T1486C 3 0.93
rs352140 GG/GA + AA TLR9 G2848A 3 0.93
rs2279744 TT/TG + GG MDM2 2 15.8
rs568408 GG/GA + AA IL12A 2 0.3
rs1800872 CC/AC + AA IL-10 C592A 5 6.67
rs1800896 GG/GA + AA IL-10 G1082A 8 22.99
rs1800795 GG/GC + CC IL-6 2 1.35
rs1800629 GG/GA + AA TNF-α-308 15 38.57
rs361525 GG/GA + AA TNF-α-238 8 372
rs3021097 CC/CT + TT IL-10 C819T 2 1.2
rs11134527 AA/AG + GG pri-miR-218 2 1.41
rs3116496 CC/CT + TT CD28 3 0.18
rs1801275 AA/AG + GG IL-4R 2 0.26
rs763110 TT/TC + CC FASL T844C 2 3.79
rs1805087 AA/AG + GG MTR A2756G 3 34.25
rs1801131 AA/AC + CC MTHFRA1298C 2 0.25
rs1052134 Ser326Cys OGG1 2 0.58
rs5275 CC/CT + TT COX-2 2 6.18
rs5742909 TT/TC + CC CTLA-318 5 2.33
rs11549465 CC/CT + TT HIF1A C1772T 2 8
rs1799864 GG/GA + AA CCR2 3 6.93
rs1800682 GG/GA + AA Fas 9 38.81
rs603965 GG/GA + AA CCND1 7 17.2
rs3025039 CC/CT + TT VEGF C936T 2 0
rs833061 TT/TC + CC VEGF T460C 2 1.94
rsl801270 CC/AC + AA p21codon 31 8 46.83
rs1801133 TT/TC + CC MTHFR C677T 9 10.53
rs62559044 AA/AT + TT IFN-r A874T 4 37.06
rs4404252 TT/TC + CC ICOS T/C 2 0.13
No, number of studies; OR, combined odds ratio; CI, confidence interval; P, P value.(CYP1A1) also showed the strongest association with
cervical cancer in the dominant effect model (OR = 0.40,
95% CI [0.25, 0.66]). For some SNPs, although hetero-
geneity was observed under the allele model and the
random effects model was used, they did not show het-
erogeneity under the dominant model; thus, the fixed ef-
fects model was then used. Some SNPs that showed a
significant association with cervical cancer in the allele
model did not show a significant association in the dom-
inant model. For example, rs3212227 (IL-12B) showed a
significant association with cervical cancer morbidity indel
Q-P I2 Model 95% CI P
0.04 0.51 Fixed 0.48[0.40,0.59] <0.00001
0.34 0.11 Fixed 0.58[0.45,0.74] <0.00001
0.08 0.45 Fixed 1.98[1.46,2.69] <0.00001
0.24 0.26 Fixed 0.68[0.56,0.84] 0.0002
0.63 0 Fixed 0.76[0.64,0.90] 0.001
0.63 0 Fixed 0.76[0.64,0.90] 0.001
<0.00001 0.94 Random 0.59[0.42,0.84] 0.003
0.59 0 Fixed 0.74[0.61,0.91] 0.004
0.15 0.4 Fixed 0.84[0.72,0.99] 0.04
0.0008 0.74 Random 0.66[0.44,0.99] 0.04
0.24 0.26 Fixed 0.70[0.49,1.00] 0.05
0.0004 0.64 Random 0.85[0.71,1.02] 0.08
<0.0001 0.98 Random 2.94[0.82,10.5] 0.10
0.27 0.17 Fixed 0.74[0.50,1.10] 0.14
0.23 0.29 Fixed 1.09[0.96,1.23] 0.18
0.92 0 Fixed 1.33[0.83,2.12] 0.24
0.61 0 Fixed 1.13[0.89,1.42] 0.31
0.05 0.74 Fixed 0.83[0.58,1.19] 0.31
<0.00001 0.94 Random 1.79[0.57,5.62] 0.32
0.62 0 Fixed 0.87[0.66,1.15] 0.33
0.45 0 Fixed 1.20[0.78,1.84] 0.40
0.01 0.84 Fixed 0.73[0.36,1.50] 0.40
0.68 0 Fixed 1.42[0.63,3.20] 0.40
0.005 0.87 Random 0.57[0.13,2.45] 0.45
0.03 0.71 Fixed 0.87[0.48,1.58] 0.65
<0.0001 0.79 Random 0.92[0.67,1.26] 0.69
0.0009 0.65 Random 0.94[0.69,1.29] 0.70
1 0 Fixed 1.08[0.72,1.62] 0.71
0.16 0.49 Fixed 1.07[0.75,1.51] 0.71
<0.00001 0.85 Random 1.07[0.71,1.62] 0.74
0.23 0.24 Fixed 1.03[0.85,1.25] 0.76
<0.00001 0.92 Random 0.92[0.41,2.09] 0.85
0.72 0 Fixed 1.01[0.84,1.22] 0.91
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model, it did not show a significant relationship with
cervical cancer (OR = 0.77, 95% CI [0.56, 1.06], p = 0.11).
Publication bias was tested using Funnel plots and
Egger’s test. We found that CCND1 (rs603965), CD28
(rs3116496) had publication bias. This bias may have re-
sulted because these SNPs were analyzed in only few
studies or because of differences in the selection of the
cases and controls.
Meta-analysis results for the recessive effect model
Based on the recessive model (AA vs. Aa + aa), there were
ten SNPs that showed heterogeneity, with a Q test P value
of <0.01. The random effects model was used for these ten
SNPs. The fixed effects model was used for the remaining
SNPs. Table 3 lists the SNPs in the recessive effect model.
Eight SNPs (rs1048943, rs16944, rs1048903, rs3212227,
rs187084, rs352140, rs2279744 and rs568408) showed a
significant association with cervical cancer. The random
effects model was used for rs2279744 (OR = 0.59, 95% CI
[0.42, 0.84]). SNP rs1048943, rs16944 and rs1048903
showed the most significant association with cervical can-
cer (0.48[0.40, 0.59], 0.58[0.45, 0.74] and 1.98[1.46, 2.69]
respectively) (Forest plots along with funnel plots was
shown in Additional file 3). At the same time, SNP
rs1048943 also showed a relatively strong association in
the allele and dominant effect model. However, the SNP
rs11134527 showed a significant association in the alleleTable 4 Meta-analysis results of special phenotypes
Gene symbol Comparison No. Q
GSTM1 postive/null 16 60.49
GSTT1 postive/null 15 69.88
G4C14-to-A4T14 P73 GG/GA + AA 2 0.61
P53 codon 72 C/G 44 268
P53 codon 72 CC/CG + GG 44 242.19
XRCC3 Codon 241 CC/CT + TT 5 6.35
G4C14-to-A4T14 P73 G/A 2 0.1
GSTP1 AA/AG + GG 2 0.97
XRCC1 Codon 194 CC/CT + TT 9 17.78
XRCC1 Codon399 GG/GA + AA 12 61.12
XRCC1 Codon399 G/A 12 203.12
XRCC1 Codon194 CC + CT/TT 9 21.11
GSTP1 A/G 2 0.03
G4C14-to-A4T14 P73 GG + GA/AA 2 0.89
P53 codon 72 CC + CG/GG 44 99.69
XRCC1 Codon399 GG + GA/AA 11 171.77
GSTP1 AA + AG/GG 2 0.1
XRCC3 Codon241 CC + CT/TT 5 13.95
XRCC1 Codon194 C/T 9 25.69
No, number of studies; OR, combined odds ratio; CI, confidence interval; P, P value.model and dominant effect model but not in the recessive
model, then we could infer that the rs11134527 mutation
of A to G can increase the risk of cervical cancer.
Meta-analysis of special phenotype
During the data collection process, we noticed that some
publications provided additional testing, such as geno-
typing for GSTM1 (positive or negative) and CYP2E1
(c1 or c2). These SNPs also were included in the meta-
analysis. The results are shown in Table 4. SNPs with
heterogeneity were tested using the random effects model.
The fixed effects model was used for the remaining SNPs.
As shown in Table 4, No SNP were significantly associated
with cervical cancer (P < 0.01).
We performed a sensitivity analysis by sequentially re-
moving each article at a time for the SNPs which num-
ber of studies was larger than or equal to 4 for the three
models. Then we found that only CTLA-318 rs5742909,
XRCC1 codon 194 in dominant genetic model and IFN-
r rs62559044 4 in allele model can affect the overall
pooled OR. The data can be seen in Additional file 4.
Meta-analysis results for SNP subgroups
In our meta-analysis, some SNPs showed heterogeneity and
then were subjected to subgroup analysis to explain the
causes of their heterogeneity. Most SNPs were reported by
only a few individual studies and were not suitable for clas-
sification into subgroups; thus, we only selected 5 SNPs forQ-P I2 Model 95% CI P
<0.00001 0.75 Random 0.70[0.53,0.92] 0.01
<0.00001 0.8 Random 0.69[0.60,0.97] 0.03
0.44 0 Fixed 0.74[0.55,1.00] 0.05
<0.00001 0.84 Random 1.14[0.99,1.34] 0.07
<0.00001 0.83 Random 1.18[0.96,1.42] 0.11
0.17 0.37 Fixed 0.82[0.63,1.06] 0.14
0.76 0 Fixed 0.83[0.65,1.07] 0.16
0.61 0 Fixed 0.88[0.69,1.11] 0.28
0.02 0.55 Fixed 0.92[0.79,1.08] 0.32
<0.0001 0.82 Random 1.18[0.84,1.64] 0.33
<0.00001 0.95 Random 1.23[0.80,1.91] 0.34
0.007 0.62 Random 0.78[0.41,1.46] 0.44
0.86 0 Fixed 0.93[0.76,1.14] 0.48
0.34 0 Fixed 1.23[0.60,2.52] 0.56
<0.0001 0.59 Random 1.06[0.90,1.23] 0.57
<0.0001 0.94 Random 1.22[0.49,3.01] 0.67
0.76 0 Fixed 0.93[0.51,1.69] 0.80
0.003 0.78 Random 0.88[0.27,2.85] 0.83
<0.00001 0.69 Random 0.99[0.73,1.33] 0.93
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Arg/Pro (44 studies), TNF-α-308 (G/A) (11 studies),
GSTM1 (positive/null) (15 studies), GSTT1 (positive/
null) (15 studies) and XRCC1 Condon399 (G/A) (12
studies). The results are listed in Table 5. For P53 codon
72 Arg/Pro, the 44 studies were divided into two sub-
groups: the Asian group (17 studies) and the Caucasians
group (11 studies). We selected the random effects
model if the SNP had heterogeneity; otherwise, we se-
lected the fixed effects model. We found that this SNP
was significant associated with cervical cancer in theTable 5 Meta-analysis results of subgroups
Gene symbol Subgroup Comparison No.
GSTT1 Total postive/null 15
Caucasians postive/null 3
Asian postive/null 10
GSTM1 Total postive/null 16
Caucasians postive/null 6
Asian postive/null 10
P53 codon 72 Total C/G 44
Caucasians C/G 11
Asian C/G 17
Total CC + GC/GG 44
Caucasians CC + GC/GG 11
Asian CC + GC/GG 17
Total CC/GC + GG 44
Caucasians CC/GC + GG 11
Asian CC/GC + GG 17
TNF-α-308 Total G/A 15
Caucasians G/A 6
Asian G/A 5
Total GG + GA/AA 15
Caucasians GG + GA/AA 6
Asian GG + GA/AA 5
Total GG/GA + AA 15
Caucasians GG/GA + AA 6
Asian GG/GA + AA 5
XRCC1 Codon 399 Total G/A 12
Caucasians G/A 3
Asian G/A 7
Total GG + GA/AA 11
Caucasians GG + GA/AA 3
Asian GG + GA/AA 7
Total GG/GA + AA 12
Caucasians GG/GA + AA 4
Asian GG/GA + AA 7
No, number of studies; OR, combined odds ratio; CI, confidence interval; P, P value.allele effect model and that the Arg allele increased the
susceptibility of cervical cancer in the Caucasians
groups but did not show a significant association in the
Asian group. The remaining 4 SNPs did not show sig-
nificantly association with cervical cancer in the two
group in the three effect model (All p values were larger
than 0.01). In addition, we found that some SNPs had
heterogeneity when considering the total population
but did not have heterogeneity when divided into sub-
groups. This phenomenon indicates that population size
is one reason for heterogeneity. However, if the SNPsQ-P Model OR 95% CI P
<0.00001 Random 0.69[0.60,0.79] 0.03
0.99 Fixed 0.89[0.69,1.30] 0.54
<0.00001 Random 0.80[0.56,1.14] 0.22
<0.00001 Random 0.70[0.53,0.92] 0.01
<0.00001 Random 0.51[0.25,1.03] 0.06
<0.00001 Random 0.79[0.60,1.02] 0.07
<0.00001 Random 1.14[0.99,1.34] 0.07
0.02 Fixed 1.14[1.02,1.27] 0.02
<0.00001 Random 1.20[0.92,1.58] 0.18
<0.0001 Random 1.06[0.90,1.23] 0.57
0.49 Fixed 1.02[0.82,1.28] 0.83
0.0009 Random 0.95[0.74,1.22] 0.70
<0.00001 Random 1.18[0.96,1.42] 0.11
0.02 Fixed 1.26[1.08,1.46] 0.003
<0.00001 Random 1.24[0.92,1.67] 0.15
<0.00001 Random 0.82[0.68,0.98] 0.03
<0.00001 Random 0.83[0.61,1.13] 0.25
0.0003 Random 0.72[0.45,1.17] 0.18
<0.00001 Random 0.82[0.57,1.18] 0.28
<0.00001 Random 0.74[0.39,1.39] 0.35
0.09 Fixed 0.97[0.79,1.19] 0.76
0.0004 Random 0.85[0.71,1.02] 0.08
0.003 Random 0.87[0.68,1.11] 0.27
0.002 Random 0.76[0.46,1.27] 0.29
<0.00001 Random 1.23[0.80,1.91] 0.34
0.004 Random 0.98[0.60,1.59] 0.92
<0.00001 Random 1.45[0.83,2.53] 0.19
<0.0001 Random 1.22[0.49,3.01] 0.67
0.46 Fixed 0.71[0.50,1.01] 0.06
<0.0001 Random 2.01[0.76,5.31] 0.16
<0.0001 Random 1.18[0.84,1.64] 0.33
0.001 Random 1.13[0.56,2.29] 0.74
<0.0001 Random 1.31[0.88,1.95] 0.18
Wang et al. BMC Medical Genetics  (2015) 16:25 Page 9 of 10also showed heterogeneity in the subgroup, other rea-
sons, such as race, may account for the presence of
heterogeneity.Discussion
In recent years, many SNPs have been demonstrated
to be associated with cervical cancer by candidate
gene association studies and GWAS. For an individual
SNP, many studies show inconsistent results, which
are sometimes even contradictory, perhaps due to false
positives, false negatives, or race or population differ-
ences. Meta-analysis is a powerful tool that can in-
crease statistical power by pooling the results of
independent studies. In this paper, we carried out a
comprehensive and systematic meta-analysis to assess
the relationship between 42 SNPs and the risk of cer-
vical cancer. We used three genetic models: the allele
model, dominant model and recessive model. Our meta-
analysis results showed that 8, 2 and 8 SNPs showed sig-
nificant associations with cervical cancer in each model,
respectively. In the three effect model, SNP rs1048943
(CYP1A1 G/A) all demonstrated the highly significant as-
sociation with cervical cancer (All p values < 0.00001). In
the recessive model, the SNPs rs16944 (IL-1βC/T) and
rs4646903 (CYPA1 T/C) also showed highly significant as-
sociation with cervical cancer (All p values < 0.00001). The
finding of positive SNPs is very important for the preven-
tion, treatment and prognosis of cervical cancer. For ex-
ample, the CYP1A1 (cytochrome P450) gene, which is
present in 15q22-24, is a key metabolic enzyme that acti-
vates polycyclic aromatic hydrocarbon, catalyzes the oxi-
dation of foreign compounds in the body, transforms
inactive carcinogens into electrophilic compounds and
promotes the formation of DNA adducts, thus generating
immunotoxicity and, finally, cancer. It has been discovered
that the polymorphism of CYP1A1 is associated with
many cancers, such as lung cancer [19], esophageal cancer
[20], endometrial cancer [21], and cervical cancer [22]. In
another example, the mutation of IL-12B rs3212227 dis-
rupts immune regulation in the host, leads to persistent
HPV infection and promotes the occurrence of cervical
cancer [23]. IL-1β is an inflammatory molecule that pro-
motes angiogenesis and inhibits the immune response of
the host. In many tumors, the patient prognosis is poor if
the expression of IL-1β is high. SNP rs16944 increases the
expression of IL-1β, thus increasing the susceptibility of
cancer [24,25]. For the 42 SNPs identified in our meta-
analysis, publication bias was tested using Funnel plots
and Egger’s test. CCND1 (dominant model, P = 0.006) and
CD28 (dominant model, P = 0.083) had significant publi-
cation bias. However, these three SNPs had no significant
association with cervical cancer. In other words, their pub-
lication bias had no influence on our positive results.Conclusion
In conclusion, our meta-analysis, which identified 42
SNPs, showed the pooling effects. Through this meta-
analysis, SNP loci that are associated with cervical can-
cer were discovered. However, some of these SNPs were
reported so few times that it was difficult to assess the
significance of their association with cervical cancer. We
plan to continue our search for articles on SNPs and
cervical cancer and will update our database accordingly.
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